230,477 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Bought by PDT Partners LLC

PDT Partners LLC bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 230,477 shares of the company’s stock, valued at approximately $3,469,000. PDT Partners LLC owned 0.50% of Pacira BioSciences at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in shares of Pacira BioSciences by 1,780.2% during the 1st quarter. Jane Street Group LLC now owns 187,531 shares of the company’s stock valued at $5,480,000 after purchasing an additional 177,557 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Pacira BioSciences by 12.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock worth $52,300,000 after buying an additional 198,936 shares during the period. Pacer Advisors Inc. lifted its stake in Pacira BioSciences by 129.4% in the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after buying an additional 2,799,434 shares in the last quarter. Legato Capital Management LLC boosted its holdings in shares of Pacira BioSciences by 74.0% in the second quarter. Legato Capital Management LLC now owns 52,913 shares of the company’s stock valued at $1,514,000 after buying an additional 22,497 shares during the period. Finally, WINTON GROUP Ltd bought a new stake in shares of Pacira BioSciences during the second quarter worth $2,726,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Stock Up 1.6 %

PCRX opened at $16.91 on Friday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock’s fifty day simple moving average is $16.46 and its 200 day simple moving average is $19.91. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $35.95. The stock has a market cap of $780.73 million, a PE ratio of -8.33 and a beta of 0.82.

Analysts Set New Price Targets

PCRX has been the topic of several research reports. Jefferies Financial Group boosted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Barclays cut their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Raymond James cut Pacira BioSciences from an “outperform” rating to a “market perform” rating in a research report on Monday, August 12th. HC Wainwright dropped their target price on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Pacira BioSciences in a research report on Friday, November 8th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.